Indications and uses
controls symptoms of diarrhea, including Travelers' Diarrhea
controls symptoms of diarrhea, including Travelers' Diarrhea
drink plenty of clear fluids to help prevent dehydration caused by diarrhea find right dose on chart. If possible, use weight to dose; otherwise, use age. adults and children 12 years and over 2 caplets after the first loose stool; 1 caplet after each subsequent loose stool; but no more than 4 caplets in 24 hours children 9-11 years (60-95 lbs) 1 caplet after the first loose stool; 1/2 caplet after each subsequent...
each caplet contains: calcium 15 mg TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN store at 20⁰C-25⁰C (68⁰F-77⁰F) see end flap for expiration date and lot number
Loperamide HCI 2 mg
Anti-diarrheal
controls symptoms of diarrhea, including Travelers' Diarrhea
Allergy alert: Do not use if you have ever had a rash or other allergic reaction to loperamide HCI
Heart alert: Taking more than directed can cause serious heart problems or death.
Do not use if you have bloody or black stool
Ask a doctor before use if you have
Ask a doctor or pharmacist before use if you are taking a prescription drug. Loperamide may interact with certain
prescription drugs.
When using this product tiredness, drowsiness or dizziness may occur. Be careful when driving or operating machinery.
Stop use and ask a doctor if
These may be signs of a serious condition.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical
help or contact a Poison Control Center right away.
| adults and children
12 years and over | 2 caplets after the first loose stool;
1 caplet after each subsequent loose stool; but no more than 4 caplets in 24 hours |
| children 9-11 years (60-95 lbs) | 1 caplet after the first loose stool; 1/2 caplet after each subsequent
loose stool; but no more than 3 caplets in 24 hours |
| children 6-8 years (48-59 lbs) | 1 caplet after the first loose stool; 1/2 caplet after each subsequent
loose stool; but no more than 2 caplets in 24 hours |
| children 2-5 years (34-47 lbs) | ask a doctor |
| children under 2 years (up to 33 lbs) | do not use |
corn starch, D&C yellow #10 aluminum lake, dibasic calcium phosphate dihydrate,
FD&C blue #1 aluminum lake, magnesium stearate, microcrystalline cellulose, silicon dioxide
call 1-800-540-3765
| Class | Version | Type | Effective |
|---|---|---|---|
| LOPERAMIDE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 10f838ef-a72b-645d-80f8-e2255205c3b1 | Product name | 6 | 20240805 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 57896-381-13 | Anti-Diarrheal | 2 in 1 CARTON | TABLET | 2 | 7 | |
| 57896-381-13 | Anti-Diarrheal | 6 in 1 BLISTER PACK | TABLET | 6 | 7 | |
| 57896-381-25 | Anti-Diarrheal | 6 in 1 BLISTER PACK | TABLET | 6 | 7 | |
| 57896-381-25 | Anti-Diarrheal | 4 in 1 CARTON | TABLET | 4 | 7 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 57896-381-12 | EA - Each | 57896-381 | b8e1e77a-a057-4cdc-aabe-0c08ef7a3a35 | 1 | 2018-04-19 |
| 57896-381-13 | EA - Each | 57896-381 | 6de128ee-ca49-40ab-bf6f-0099f7afc3ea | 1 | 2022-03-09 |
| 57896-381-24 | EA - Each | 57896-381 | 564ffe4d-6390-4563-b3ab-22b82d71dbdf | 1 | 2013-06-04 |
| 57896-381-25 | EA - Each | 57896-381 | caeb2e78-e036-4961-bb90-c907fd5ef8d0 | 1 | 2022-03-09 |
| 57896-381-96 | EA - Each | 57896-381 | 25449e42-7e92-49f5-b5db-ac40c01a3898 | 1 | 2017-03-06 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | ACTIVE INGREDIENT | 77TI35393C | 1 | |
| LOPERAMIDE | ACTIVE MOIETY | 6X9OC3H4II | 1 | |
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | INACTIVE INGREDIENT | L11K75P92J | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| D&C YELLOW NO. 10 | INACTIVE INGREDIENT | 35SW5USQ3G | 1 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| STARCH, CORN | INACTIVE INGREDIENT | O8232NY3SJ | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 57896-381 | 57896-381-25, 57896-381-13 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| STARCH, CORN | O8232NY3SJ | IACT |
| D&C YELLOW NO. 10 | 35SW5USQ3G | IACT |
| FD&C BLUE NO. 1 | H3R47K3TBD | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| LOPERAMIDE HYDROCHLORIDE | 77TI35393C | ACTIB |
| CELLULOSE, MICROCRYSTALLINE | OP1R32D61U | IACT |
| DIBASIC CALCIUM PHOSPHATE DIHYDRATE | O7TSZ97GEP | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET / ORAL | 80 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET / ORAL | 2240 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET / ORAL | 80 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET / ORAL | 27.53 mg | ||
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET / ORAL | 2240 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / ORAL | 1116 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / ORAL | 1116 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / ORAL | 1116 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET / ORAL | 80 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET / ORAL | 2240 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET / ORAL | 27.53 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET / ORAL | 27.53 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A076497-001 | LOPERAMIDE HYDROCHLORIDE | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A076497-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 2003-06-10 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Anti-Diarrheal | LOPERAMIDE HCL | Geri-Care Pharmaceutical Corp | 0ecca2cd-c971-47b2-a2ac-ae7842dd4264 | 2025-06-11 | Warnings | 57896-381-25 57896-381-13 57896-381 57896038125 57896038113 37510ed6-1ec9-14e2-e063-6394a90a2609 0ecca2cd-c971-47b2-a2ac-ae7842dd4264 |
Adverse event summaries are temporarily unavailable. Other product information remains available.